Andrea Richardson, M.D., Ph.D, Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Andrea Richardson, M.D., Ph.D, Dana-Farber Cancer Institute

Caption

Andrea Richardson, M.D., Ph.D, and her colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Credit

Sam Ogden

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.